A study in Alzheimer's & Dementia has demonstrated the high accuracy of plasma p-tau217 as a blood-based biomarker for ...
A protein that impacts Alzheimer’s disease offers new opportunities for targeted treatments, although its cell-specific ...
News Medical on MSN6d
CD2AP and Alzheimer’s disease: A key regulator of neurodegeneration and potential therapeutic targetA comprehensive Thought Leaders Invited Review in Brain Medicine highlights the crucial role of CD2-associated protein (CD2AP ...
A study in Alzheimer's & Dementia , a leading journal in dementia research, has demonstrated the high accuracy of plasma p-tau217 as a blood-based ...
ScienceAlert on MSN3d
Anti-Amyloid Drug May Delay Alzheimer's Symptoms in Those at Risk, Clinical Trial FindsA method for slowing disease progress in Alzheimer's patients may also delay onset in people predisposed to the disease who ...
While research has determined that there is no association between having AMD and then developing Alzheimer's or dementia, ...
Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...
Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.
“This follow-up study of gantenerumab, an anti-amyloid drug that previously failed to slow cognitive decline in people at risk of Alzheimer’s disease, suggests that extended use of anti-amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback